Literature DB >> 31119008

Development of Periungual Pyogenic Granuloma with Associated Paronychia Following Isotretinoin Therapy: A Case Report and a Review of the Literature.

Conrad Benedetto1,2, Dave Crasto1,2, Leila Ettefagh1,2, Navid Nami1,2.   

Abstract

The development of periungual pyogenic granulomas while taking the oral acne drug isotretinoin is a known yet uncommon and potentially severe side effect of the oral vitamin A derivative. Previous reports have detailed the development of pyogenic granulomas most commonly arising at sites of previous acne lesions as well as both subungual and periungual locations, with associated paronychia, bleeding, and discomfort. This is thought to arise as a result of the nail bed's fragility and propensity toward spicule formation brought on by the proliferative action of isotretinoin. Here, we report a case of periungual pyogenic granuloma with associated paronychia in a patient taking oral isotretinoin. A review of the pathogenesis and available treatment modalities based on the current literature is provided.

Entities:  

Keywords:  Isotretinoin; drug-induced; paronychia; periungual; pyogenic granuloma

Year:  2019        PMID: 31119008      PMCID: PMC6508482     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  3 in total

Review 1.  [The most common benign cutaneous neoplasms of vascular, muscular, and adipose tissue and their treatment].

Authors:  Alexandra-Irina Butacu; Iulia-Elena Negulet; Emanuela-Domnica Boieriu; Ioana-Simona Dinu; Andrew Mihalache; Bogdan Mastalier; Carmen Maria Salavastru; Klaus Fritz; George-Sorin Tiplica
Journal:  Hautarzt       Date:  2022-01-18       Impact factor: 0.751

2.  Multiple disseminated pyogenic granuloma post-oil burning-Review literature.

Authors:  Fariba Iraji; Minoo Jelvan; Zakiye Ganjei; Parvin Rajabi
Journal:  Clin Case Rep       Date:  2020-11-06

Review 3.  Childhood Vascular Tumors.

Authors:  Harriet Bagnal Hinen; Cameron C Trenor; Lara Wine Lee
Journal:  Front Pediatr       Date:  2020-10-22       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.